Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CLAZAKIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| MIDOSTAURIN | ? unclear | Mechanistic | DGIdb | |
| ECHINACEA EXTRACT | ? unclear | Mechanistic | DGIdb | |
| NELFINAVIR | ? unclear | Mechanistic | DGIdb | |
| SELECTIVE ESTROGEN RECEPTOR MODULATOR | ? unclear | Mechanistic | DGIdb | |
| SIGNAL TRANSDUCTION INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| OLOKIZUMAB | ? unclear | Mechanistic | DGIdb | |
| IBUDILAST | ? unclear | Mechanistic | DGIdb | |
| VITAMIN A PALMITATE | ? unclear | Mechanistic | DGIdb | |
| IFOSFAMIDE | ? unclear | Mechanistic | DGIdb | |
| SITAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| METRONIDAZOLE | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| PACIBEKITUG | ↓ inhibits | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| SIRUKUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| HMG-COA REDUCTASE INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| SAFINGOL | ? unclear | Mechanistic | DGIdb | |
| ENZYME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| RITUXIMAB | ? unclear | Mechanistic | DGIdb | |
| INFLIXIMAB | ? unclear | Mechanistic | DGIdb | |
| C326 | ? unclear | Mechanistic | DGIdb | |
| GEMFIBROZIL | ? unclear | Mechanistic | DGIdb | |
| ZILTIVEKIMAB | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| OSIMERTINIB | ? unclear | Mechanistic | DGIdb | |
| BINETRAKIN | ? unclear | Mechanistic | DGIdb | |
| ALOGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| TENELIGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| CHINESE HERBS | ? unclear | Mechanistic | DGIdb | |
| TOCILIZUMAB | ? unclear | Mechanistic | DGIdb | |
| LINAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| DOCETAXEL ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| VILDAGLIPTIN | ? unclear | Mechanistic | DGIdb | |
| LINEZOLID | ? unclear | Mechanistic | DGIdb | |
| SELENIUM | ? unclear | Mechanistic | DGIdb | |
| SAQUINAVIR | ? unclear | Mechanistic | DGIdb | |
| PAREGORIC | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 181 agents ranked by evidence tier.
NR3C1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METHYLPREDNISOLONE | ↑ activates | Mechanistic | DGIdb | |
| FOSDAGROCORAT | ↑ activates | Mechanistic | DGIdb | |
| ZK216348 | ↑ activates | Mechanistic | DGIdb | |
| PHENYLMERCURIC ACETATE | ? unclear | Mechanistic | DGIdb | |
| TNF-ALPHA | ? unclear | Mechanistic | DGIdb | |
| HYDROCORTAMATE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| TRIAMCINOLONE | ↑ activates | Mechanistic | DGIdb | |
| BUDESONIDE | ↑ activates | Mechanistic | DGIdb | |
| ANTICONVULSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| FLUTICASONE FUROATE | ↑ activates | Mechanistic | DGIdb | |
| METHYLPREDNISOLONE ACETATE | ↑ activates | Mechanistic | DGIdb | |
| DAGROCORAT | ↑ activates | Mechanistic | DGIdb | |
| MIFEPRISTONE | ↓ inhibits | Mechanistic | 0.24 nM (Ki) | DGIdb |
| TESTOSTERONE PROPIONATE | ? unclear | Mechanistic | DGIdb | |
| FLURANDRENOLIDE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1915271 | ? unclear | Mechanistic | DGIdb | |
| CHRYSIN | ? unclear | Mechanistic | DGIdb | |
| FLUOXYMESTERONE | ? unclear | Mechanistic | DGIdb | |
| LOTEPREDNOL | ↑ activates | Mechanistic | DGIdb | |
| DIFLUPREDNATE | ↑ activates | Mechanistic | DGIdb | |
| CORT 108297 | ↓ inhibits | Mechanistic | DGIdb | |
| PROGESTERONE | ? unclear | Mechanistic | 30.5 nM (Ki) | DGIdb |
| BETAMETHASONE SODIUM PHOSPHATE | ↑ activates | Mechanistic | DGIdb | |
| ANTIDEPRESSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| HYDROCORTISONE BUTYRATE | ↑ activates | Mechanistic | DGIdb | |
| VELSECORAT | ↑ activates | Mechanistic | DGIdb | |
| FLUMETHASONE PIVALATE | ↑ activates | Mechanistic | DGIdb | |
| AMCINONIDE | ↑ activates | Mechanistic | DGIdb | |
| CYPROTERONE ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| C108297 | ↑ activates | Mechanistic | DGIdb | |
| COMPOUND 17 [PMID: 29741897] | ↑ activates | Mechanistic | DGIdb | |
| FLUOCINONIDE | ↑ activates | Mechanistic | DGIdb | |
| MAPRACORAT | ↑ activates | Mechanistic | DGIdb | |
| CLOBETASOL PROPIONATE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL210411 | ? unclear | Mechanistic | DGIdb | |
| FLUOCINOLONE ACETONIDE | ↑ activates | Mechanistic | DGIdb | |
| BETAMETHASONE | ↑ activates | Mechanistic | DGIdb | |
| BECLOMETHASONE DIPROPIONATE | ↑ activates | Mechanistic | DGIdb | |
| FLUNISOLIDE ANHYDROUS | ↑ activates | Mechanistic | DGIdb | |
| CORTISONE ACETATE | ↑ activates | Mechanistic | DGIdb |
Showing top 40 of 264 agents ranked by evidence tier.
PTGS2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CURCUMIN PYRAZOLE | ? unclear | Mechanistic | DGIdb | |
| CAPECITABINE | ? unclear | Mechanistic | DGIdb | |
| DIFLUNISAL | ↓ inhibits | Mechanistic | DGIdb | |
| ROFECOXIB | ↓ inhibits | Mechanistic | 530.0 nM (IC50) | DGIdb |
| KETOROLAC TROMETHAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| DEXIBUPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| BALSALAZIDE | ? unclear | Mechanistic | DGIdb | |
| ESFLURBIPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| NAPROXEN ETEMESIL | ? unclear | Mechanistic | DGIdb | |
| SUPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| PEPTIDE 30 [PMID: 27019010] | ↓ inhibits | Mechanistic | DGIdb | |
| NEPAFENAC | ↓ inhibits | Mechanistic | DGIdb | |
| APRICOXIB | ↓ inhibits | Mechanistic | DGIdb | |
| APAZONE | ↓ inhibits | Mechanistic | DGIdb | |
| SALICYLIC ACID | ? unclear | Mechanistic | DGIdb | |
| TIAPROFENIC ACID | ? unclear | Mechanistic | DGIdb | |
| KETOPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| RESERPINE | ? unclear | Mechanistic | DGIdb | |
| NS-398 | ↓ inhibits | Mechanistic | DGIdb | |
| NABUMETONE | ↓ inhibits | Mechanistic | DGIdb | |
| SULINDAC | ↓ inhibits | Mechanistic | DGIdb | |
| ETODOLAC | ↓ inhibits | Mechanistic | DGIdb | |
| MEFENAMIC ACID | ↓ inhibits | Mechanistic | DGIdb | |
| DICLOFENAC SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| ETORICOXIB | ↓ inhibits | Mechanistic | DGIdb | |
| VALDECOXIB | ↓ inhibits | Mechanistic | DGIdb | |
| IBUFENAC | ↓ inhibits | Mechanistic | DGIdb | |
| DEXKETOPROFEN | ↓ inhibits | Mechanistic | DGIdb | |
| GLAFENINE | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 9 [KUMAR ET AL., 2019] | ↓ inhibits | Mechanistic | DGIdb | |
| RESVERATROL | ↓ inhibits | Mechanistic | DGIdb | |
| SWE101 | ↓ inhibits | Mechanistic | DGIdb | |
| INDOMETHACIN | ↓ inhibits | Mechanistic | 5.9 nM (IC50) | DGIdb |
| NAPROXCINOD | ↓ inhibits | Mechanistic | DGIdb | |
| HR1405-01 | ↓ inhibits | Mechanistic | DGIdb | |
| DICLOFENAC ETALHYALURONATE SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 12A [PMID: 29031075] | ↓ inhibits | Mechanistic | DGIdb | |
| TOLMETIN SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| OXYPHENBUTAZONE | ↓ inhibits | Mechanistic | DGIdb | |
| DICLOFENAC POTASSIUM | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 309 agents ranked by evidence tier.
SCN9A
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TETRODOTOXIN | ↓ inhibits | Mechanistic | DGIdb | |
| XEN403 | ↓ inhibits | Mechanistic | DGIdb | |
| IRAMPANEL | ↓ inhibits | Mechanistic | DGIdb | |
| XEN907 | ↓ inhibits | Mechanistic | DGIdb | |
| N-ME-AMINOPYRIMIDINONE 9 | ↓ inhibits | Mechanistic | DGIdb | |
| PF‐06526290 | ↓ inhibits | Mechanistic | DGIdb | |
| QUINIDINE POLYGALACTURONATE | ↓ inhibits | Mechanistic | DGIdb | |
| VIXOTRIGINE | ↓ inhibits | Mechanistic | DGIdb | |
| LIDOCAINE | ↓ inhibits | Mechanistic | DGIdb | |
| FUNAPIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CD2+ | ↓ inhibits | Mechanistic | DGIdb | |
| PHENYTOIN SODIUM | ↓ inhibits | Mechanistic | DGIdb | |
| HEXYLCAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ESLICARBAZEPINE ACETATE | ↓ inhibits | Mechanistic | DGIdb | |
| DICHLOROBENZYL ALCOHOL | ↓ inhibits | Mechanistic | DGIdb | |
| PROPOFOL | ? unclear | Mechanistic | DGIdb | |
| OXCARBAZEPINE | ↓ inhibits | Mechanistic | DGIdb | |
| ORPHENADRINE CITRATE | ↓ inhibits | Mechanistic | DGIdb | |
| NERISPIRDINE | ↓ inhibits | Mechanistic | DGIdb | |
| CHLOROPROCAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| MEPHENYTOIN | ↓ inhibits | Mechanistic | DGIdb | |
| ANP-230 | ↓ inhibits | Mechanistic | DGIdb | |
| ABBV-318 | ↓ inhibits | Mechanistic | DGIdb | |
| MEPIVACAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| AMOROLFINE | ↓ inhibits | Mechanistic | DGIdb | |
| RUFINAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| EVENAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| SAFINAMIDE | ? unclear | Mechanistic | DGIdb | |
| NKTR-171 | ↓ inhibits | Mechanistic | DGIdb | |
| RG6029 | ↓ inhibits | Mechanistic | DGIdb | |
| RALFINAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ZONISAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| BIIB-095 | ? unclear | Mechanistic | DGIdb | |
| RG7893 | ↓ inhibits | Mechanistic | DGIdb | |
| ARTICAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| DISOPYRAMIDE PHOSPHATE | ↓ inhibits | Mechanistic | DGIdb | |
| PROPOXYCAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| TOCAINIDE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| TETRACAINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| MERETHOXYLLINE PROCAINE | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 280 agents ranked by evidence tier.
TGFB1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LY-2382770 | ↓ inhibits | Mechanistic | DGIdb | |
| ETOPOSIDE | ? unclear | Mechanistic | DGIdb | |
| BROXURIDINE | ? unclear | Mechanistic | DGIdb | |
| INOSITOL | ? unclear | Mechanistic | DGIdb | |
| D-ALPHA-TOCOPHEROL | ? unclear | Mechanistic | DGIdb | |
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| PROTEASOME INHIBITOR | ? unclear | Mechanistic | DGIdb | |
| FRESOLIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| THERAPEUTIC ANDROGEN | ? unclear | Mechanistic | DGIdb | |
| GALUNISERTIB | ? unclear | Mechanistic | DGIdb | |
| TOREMIFENE | ? unclear | Mechanistic | DGIdb | |
| TRETINOIN | ? unclear | Mechanistic | DGIdb | |
| BINTRAFUSP ALFA | ~ modulates | Mechanistic | DGIdb | |
| PIRFENIDONE | ? unclear | Mechanistic | DGIdb | |
| DOXORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| GOSSYPOL | ? unclear | Mechanistic | DGIdb | |
| EMODIN | ? unclear | Mechanistic | DGIdb | |
| IDOXURIDINE | ? unclear | Mechanistic | DGIdb | |
| HYDROCORTISONE BUTYRATE | ? unclear | Mechanistic | DGIdb | |
| CLADRIBINE | ? unclear | Mechanistic | DGIdb | |
| TG-C | ? unclear | Mechanistic | DGIdb | |
| ASPIRIN | ? unclear | Mechanistic | DGIdb | |
| DISITERTIDE | ? unclear | Mechanistic | DGIdb | |
| RAMIPRIL | ? unclear | Mechanistic | DGIdb | |
| ANTISENSE OLIGONUCLEOTIDES | ? unclear | Mechanistic | DGIdb | |
| HEPARAN SULFATE | ? unclear | Mechanistic | DGIdb | |
| TRIAMCINOLONE | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL VALERATE | ? unclear | Mechanistic | DGIdb | |
| AMIFOSTINE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| KEYHOLE LIMPET HEMOCYANIN | ? unclear | Mechanistic | DGIdb | |
| LUSPATERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| ATENOLOL | ? unclear | Mechanistic | DGIdb | |
| GALLIUM NITRATE | ? unclear | Mechanistic | DGIdb | |
| ANTIOXIDANT | ? unclear | Mechanistic | DGIdb | |
| FENRETINIDE | ? unclear | Mechanistic | DGIdb | |
| GENISTEIN | ? unclear | Mechanistic | DGIdb | |
| RETINOIC ACID AGENT | ? unclear | Mechanistic | DGIdb | |
| OCTREOTIDE ACETATE | ? unclear | Mechanistic | DGIdb | |
| THERAPEUTIC MELATONIN | ? unclear | Mechanistic | DGIdb | |
| TCDD | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 62 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DICLOFENAC SODIUM | ? unclear | Mechanistic | DGIdb | |
| RDP58 | ? unclear | Mechanistic | DGIdb | |
| METHYLENE BLUE | ? unclear | Mechanistic | DGIdb | |
| ORTATAXEL | ? unclear | Mechanistic | DGIdb | |
| CERTOLIZUMAB PEGOL | ↓ inhibits | Mechanistic | DGIdb | |
| OZORALIZUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| THALIDOMIDE | ? unclear | Mechanistic | DGIdb | |
| HUANG LIAN | ? unclear | Mechanistic | DGIdb | |
| GOLIMUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| CYCLOSPORINE | ? unclear | Mechanistic | DGIdb | |
| DOCETAXEL ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| HALOFUGINONE | ? unclear | Mechanistic | DGIdb | |
| ETANERCEPT | ↓ inhibits | Mechanistic | DGIdb | |
| ISIS 104838 | ? unclear | Mechanistic | DGIdb | |
| GEMCITABINE | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| INSULIN, REGULAR, HUMAN | ? unclear | Mechanistic | DGIdb | |
| DIDANOSINE | ? unclear | Mechanistic | DGIdb | |
| 5,7-DIHYDROXY-4-METHYLCOUMARIN | ? unclear | Mechanistic | DGIdb | |
| SOBLIDOTIN | ? unclear | Mechanistic | DGIdb | |
| STAVUDINE | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| MEROPENEM ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| AMPHOTERICIN B LIPOSOMAL | ? unclear | Mechanistic | DGIdb | |
| MIDAZOLAM HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| RIFAMPIN | ? unclear | Mechanistic | DGIdb | |
| AVX-470 | ? unclear | Mechanistic | DGIdb | |
| KETOROLAC TROMETHAMINE | ? unclear | Mechanistic | DGIdb | |
| PRAZOSIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| RISPERIDONE | ? unclear | Mechanistic | DGIdb | |
| BENZO[E]PYRENE | ? unclear | Mechanistic | DGIdb | |
| ETHAMBUTOL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| REMTOLUMAB | ↓ inhibits | Mechanistic | DGIdb | |
| SPIRONOLACTONE | ? unclear | Mechanistic | DGIdb | |
| OMEPRAZOLE | ? unclear | Mechanistic | DGIdb | |
| CARBOPLATIN | ? unclear | Mechanistic | DGIdb | |
| MITOMYCIN C ANALOG KW-2149 | ? unclear | Mechanistic | DGIdb | |
| NAFAMOSTAT | ? unclear | Mechanistic | DGIdb | |
| ABBV-3373 | ~ modulates | Mechanistic | DGIdb | |
| BACILLUS CALMETTE-GUERIN ANTIGEN | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 287 agents ranked by evidence tier.
TRPV1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| RHTX | ↑ activates | Mechanistic | DGIdb | |
| ABT-102 | ↓ inhibits | Mechanistic | DGIdb | |
| ASIVATREP | ↓ inhibits | Mechanistic | DGIdb | |
| BCTC | ↓ inhibits | Mechanistic | DGIdb | |
| MAVATREP | ↓ inhibits | Mechanistic | DGIdb | |
| POLYGODIAL | ? unclear | Mechanistic | DGIdb | |
| ALLICIN | ↓ inhibits | Mechanistic | DGIdb | |
| JTS-653 | ↓ inhibits | Mechanistic | DGIdb | |
| SB452533 | ↓ inhibits | Mechanistic | DGIdb | |
| MR-1817 | ↓ inhibits | Mechanistic | DGIdb | |
| GRC-6211 | ↓ inhibits | Mechanistic | DGIdb | |
| ACETAMINOPHEN | ↑ activates | Mechanistic | DGIdb | |
| DWP05195 | ↓ inhibits | Mechanistic | DGIdb | |
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| CAPSAICIN | ↑ activates | Mechanistic | 19.95 nM (EC50) | DGIdb |
| AMG517 | ↓ inhibits | Mechanistic | DGIdb | |
| 5S-HETE | ↑ activates | Mechanistic | DGIdb | |
| BENZYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| MASOPROCOL | ? unclear | Mechanistic | DGIdb | |
| [3H]RESINIFERATOXIN | ↑ activates | Mechanistic | DGIdb | |
| [3H]A778317 | ↓ inhibits | Mechanistic | DGIdb | |
| CAPSAZEPINE | ↓ inhibits | Mechanistic | 120.0 nM (Ki) | DGIdb |
| NABIXIMOLS | ? unclear | Mechanistic | DGIdb | |
| H+ | ↑ activates | Mechanistic | DGIdb | |
| RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN | ? unclear | Mechanistic | DGIdb | |
| NADA | ↓ inhibits | Mechanistic | DGIdb | |
| ZUCAPSAICIN | ↑ activates | Mechanistic | DGIdb | |
| SB366791 | ↓ inhibits | Mechanistic | DGIdb | |
| GRC-15300 | ? unclear | Mechanistic | DGIdb | |
| MRS-1477 | ~ modulates | Mechanistic | DGIdb | |
| ANANDAMIDE | ↑ activates | Mechanistic | DGIdb | |
| JNJ17203212 | ↓ inhibits | Mechanistic | DGIdb | |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| AZD1386 | ↓ inhibits | Mechanistic | DGIdb | |
| CAMPHOR OIL | ↑ activates | Mechanistic | DGIdb | |
| ISOPROPYL ISOTHIOCYANATE | ? unclear | Mechanistic | DGIdb | |
| VOACANGINE | ? unclear | Mechanistic | DGIdb | |
| FERRUGINENE B | ? unclear | Mechanistic | DGIdb | |
| PHENYLACETYLRINVANIL | ↑ activates | Mechanistic | DGIdb |
Showing top 40 of 187 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| APIGENIN | ? unclear | Mechanistic | 18000.0 nM (IC50) | DGIdb |
| ACORAMIDIS | ~ modulates | Mechanistic | 314.0 nM (Kd) | DGIdb |
| INOTERSEN | ? unclear | Mechanistic | DGIdb | |
| ACORAMIDIS HYDROCHLORIDE | ~ modulates | Mechanistic | DGIdb | |
| TAFAMIDIS | ~ modulates | Mechanistic | 274.0 nM (Kd) | DGIdb |
| MASOPROCOL | ? unclear | Mechanistic | DGIdb | |
| PATISIRAN | ? unclear | Mechanistic | DGIdb | |
| ETHYL CAFFEATE | ? unclear | Mechanistic | 23000.0 nM (EC50) | DGIdb |
| REVUSIRAN | ? unclear | Mechanistic | DGIdb | |
| EPLONTERSEN | ? unclear | Mechanistic | DGIdb | |
| CAFFEIC ACID PHENETHYL ESTER | ? unclear | Mechanistic | 8600.0 nM (EC50) | DGIdb |
| DIHYDROGUAIARETIC ACID | ? unclear | Mechanistic | 6300.0 nM (EC50) | DGIdb |
| VUTRISIRAN | ? unclear | Mechanistic | DGIdb | |
| TAFAMIDIS MEGLUMINE | ~ modulates | Mechanistic | DGIdb | |
| BENZYL CAFFEATE | ? unclear | Mechanistic | 16000.0 nM (EC50) | DGIdb |
| PATISIRAN SODIUM | ? unclear | Mechanistic | Open Targets | |
| INOTERSEN SODIUM | ? unclear | Mechanistic | Open Targets | |
| VUTRISIRAN SODIUM | ? unclear | Mechanistic | Open Targets | |
| EPLONTERSEN SODIUM | ? unclear | Mechanistic | Open Targets | |
| TRICLOSAN | ↓ inhibits | Mechanistic | 53500.0 nM (IC50) | ChEMBL |
| CHEMBL394034 | ↓ inhibits | Mechanistic | 120.0 nM (Kd) | ChEMBL |
| CHEMBL240165 | ↓ inhibits | Mechanistic | 42.0 nM (Kd) | ChEMBL |
| CHEMBL241454 | ↓ inhibits | Mechanistic | 27.0 nM (Kd) | ChEMBL |
| CHEMBL241453 | ↓ inhibits | Mechanistic | 88.0 nM (Kd) | ChEMBL |
| CHEMBL240808 | ↓ inhibits | Mechanistic | 27.0 nM (Kd) | ChEMBL |
| CHEMBL438498 | ↓ inhibits | Mechanistic | 0.2 nM (Kd) | ChEMBL |
| CHEMBL240806 | ↓ inhibits | Mechanistic | 0.3 nM (Kd) | ChEMBL |
| CHEMBL240805 | ↓ inhibits | Mechanistic | 5.7 nM (Kd) | ChEMBL |
| CHEMBL240804 | ↓ inhibits | Mechanistic | 13.9 nM (Kd) | ChEMBL |
| DEXTROTHYROXINE | ↓ inhibits | Mechanistic | 7170.0 nM (IC50) | ChEMBL |
| CHEMBL241025 | ↓ inhibits | Mechanistic | 1940.0 nM (IC50) | ChEMBL |
| CHEMBL240807 | ↓ inhibits | Mechanistic | 3160.0 nM (IC50) | ChEMBL |
| CHEMBL392872 | ↓ inhibits | Mechanistic | 41000.0 nM (IC50) | ChEMBL |
| CHEMBL238590 | ↓ inhibits | Mechanistic | 45000.0 nM (IC50) | ChEMBL |
| CHEMBL392873 | ↓ inhibits | Mechanistic | 55000.0 nM (IC50) | ChEMBL |
| CHEMBL241575 | ↓ inhibits | Mechanistic | 20000.0 nM (IC50) | ChEMBL |
| CHEMBL241573 | ↓ inhibits | Mechanistic | 20000.0 nM (IC50) | ChEMBL |
| FLUFENAMIC ACID | ↓ inhibits | Mechanistic | 2900.0 nM (IC50) | ChEMBL |
| CHEMBL60569 | ↓ inhibits | Mechanistic | 6300.0 nM (IC50) | ChEMBL |
| CHEMBL571374 | ↓ inhibits | Mechanistic | 11000.0 nM (IC50) | ChEMBL |
Showing top 40 of 153 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Carpal Tunnel Syndrome: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
Carpal tunnel syndrome (CTS) is a common peripheral nerve entrapment disorder caused by compression of the median nerve at the wrist. This study is a comparative study designed to evaluate the efficacy of three ultrasound-guided injection treatments for patients with mild to moderate CTS: hyaluronic...
Carpal Tunnel Syndrome (CTS) is a compressive neuropathy caused by chronic compression of the median nerve within the carpal tunnel, resulting in pain, numbness, tingling, and impaired hand function. This study is a randomized controlled trial with a pre- and post-intervention experimental design to...
The aim of this study is to compare the effects of ultrasound-guided hydrodissection with 5% dextrose and perineural corticosteroid injection on the clinical parameters of carpal tunnel syndrome, as well as to evaluate the long-term efficacy of these treatments.
Carpal Tunnel Syndrome (CTS) is a common condition that causes numbness, tingling, pain, and weakness in the hand due to compression of the median nerve at the wrist. It can affect daily activities, work performance, and quality of life. While surgery is effective in severe cases, many patients with...
Carpal tunnel syndrome (CTS) causes numbness and pain in the hand and arm, and is an important cause of work absence and disability. The aim of the NOR-CACTUS Trial is to compare outcomes of a treatment strategy where the initial treatment is up to two ultrasound-guided corticosteroid injections, fo...
This research study is being conducted to investigate the safety and effectiveness of the drug Fisetin for mild or moderate carpal tunnel syndrome (CTS).
Effectiveness of corticosteroid and 5% dextrose versus USG-guided ozone injections in patients with carpal tunnel syndrome: Three blind randomized studies
The goal of this clinical trial is to assess the effectiveness and safety of an oral combination of alpha lipoic acid (ALA) and vitamin B complex in treating mild to moderate carpal tunnel syndrome (CTS) in adults. The main questions it aims to answer are: * Does the combination of ALA and vitamin B...
PRP represents a promising, nonsurgical option for patients with carpal tunnel syndrome (CTS) with improvement in symptoms compared to placebo, conservative treatment, and local corticosteroid injections at 3-months postintervention. However, the lack of significant long-term results in pain and fun...
It is aimed to compare the effects of different conservative methods on the clinical condition of the patients, hand grip and pinch strengths and wrist muscle strengths in patients with carpal tunnel syndrome.
This study is being conducted to determine whether addition of a longer-acting local anesthetic to our current anesthetic protocol improves the post-operative pain after carpal tunnel release. Participants undergoing carpal tunnel release (CTR) will be randomly assigned to one of two groups: the sta...
This study was a prospective randomized double-blind clinical trial conducted at the Physical Medicine and Rehabilitation Clinic of a local research and training hospital in Turkey from October 2023 and May 2024. Patients diagnosed with CTS were classified into three groups: severe, mild, and modera...
USG guided injections to relieve carpal tunnel syndrome with dextrose water or steroid or PRP
Therefore, we aimed to evaluate the effectiveness of vitamin D replacement therapy on pain, electrophysiological parameters, ultrasonographic measurement results and functional status scales in CTS patients with low serum vitamin D levels.
This clinical trial aims to evaluate the effect of a single local platelet-rich plasma injection Versus local steroid injection in treating mild idiopathic carpal tunnel syndrome regarding pain relief and function improvement and electrophysiological studies of the median nerve as a baseline and dur...
Agents Found By Disease-Level Search
Searched directly from “Carpal Tunnel Syndrome” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
36 agents shown (approved or with trial evidence) — 32 not found by the gene-target search above.
platelet rich plasmaNOT in gene-target list
shock waveNOT in gene-target list
Carpal tunnel releaseNOT in gene-target list
Ischemic Compression (thumb Pressure)NOT in gene-target list
Lidocaine
CorticoidsNOT in gene-target list
CTS-6 Evaluation ToolNOT in gene-target list
Ibuprofen ArginineNOT in gene-target list
GabapentinNOT in gene-target list
wrist splintNOT in gene-target list
5% dextrose injection using USG-guided nerve hydrodissection methodNOT in gene-target list
Sono-guided injection with ES135NOT in gene-target list
Nerve conduction studiesNOT in gene-target list
Pulsed RadiofrequencyNOT in gene-target list
Kinesio tapingNOT in gene-target list
pulsed electromagnetic fieldNOT in gene-target list
Incisionless Threaded Carpal TunnelNOT in gene-target list
Standard Mini-Open Carpal TunnelNOT in gene-target list
dextrose 5% median nerve hydrodissectionNOT in gene-target list
Study groupNOT in gene-target list
Control groupNOT in gene-target list
5% DextroseNOT in gene-target list
Betamethasone and local anestheticNOT in gene-target list
Acetaminophen
Ketorolac Tromethamine
Combined carpal tunnel and lacertus releaseNOT in gene-target list
Ropivacaine
chirurgie canal carpienNOT in gene-target list
extracorporeal shockwave therapyNOT in gene-target list
Distal Radius Fracture Fixation with Observation.NOT in gene-target list
Neuromuscular tapingNOT in gene-target list
Aquatic TherapyNOT in gene-target list
Neuro-Dynamic TechniqueNOT in gene-target list
two-component skin adhesive Glubran Tiss 2®NOT in gene-target list
skin stitched with transcutaneous nylon sutureNOT in gene-target list
MonocrylNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.